Artivion (AORT) Stock Forecast & Price Target

Artivion is positioned favorably because its core aortic-centric portfolio is supported by multiple growth drivers, especially AMDS and NEXUS, while temporary setbacks from a stent graft supplier issue, AMDS ordering friction, and softer Middle Eastern sales appear transitory rather than structural. The company’s margin profile has also improved meaningfully, with EBITDA margin rising from 13.3% in 2022 to 20.3% in 2025 and EBITDA compounding at a 29% CAGR, suggesting strong operating leverage as higher-margin products scale. In addition, On-X is benefiting from stronger clinical data and a ~$100M U.S. TAM expansion, reinforcing the view that revenue growth and profitability can continue to strengthen across North America, EMEA, LATAM, and APAC.

Artivion is facing a fragile growth profile because 49% of 2024 revenue came from outside North America, leaving the company exposed to tariffs, corruption/compliance burdens, reimbursement shifts, and uneven international execution. Its tissue preservation services are also a major revenue pillar, yet supply constraints, regulatory changes, negative publicity, and restrictions on tissue distribution could disrupt volumes and pricing. On top of that, the company carries meaningful quality and regulatory risk, including potential recalls, EU MDR reclassification, FDA scrutiny of SGPV, and EtO sterilization pressure, while the bear case already assumes only mid-single-digit-or-lower growth from disappointing launches and weak expansion.